Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives

Abstract

Melanoma is an aggressive form of skin cancer characterized by poor prognosis and high mortality. The development of targeted agents based on the discovery of driver mutations as well as the implementation of checkpoint inhibitor-based immunotherapy represents a major breakthrough in the treatment of metastatic melanoma. However, in both cases the development of drug resistance and immune escape mechanisms as well as the lack of predictive biomarkers limits their extraordinary clinical efficacy. In this article, we summarize the available therapeutic options for patients with metastatic melanoma, outline the mechanisms implicated in the resistance to both targeted agents and immunotherapy, discuss potential predictive biomarkers and outline future therapeutic approaches under investigation.

Keywords: BRAF inhibitor resistance; Melanoma; PD-1; PD-L1; immune checkpoint molecules; immunotherapy; immunotherapy resistance; predictive biomarkers; targeted therapy..